Join our daily newsletter At The Bell to receive exclusive market insights
Compumedics (ASX:CMP) has seen record sales orders and continued momentum across its core and emerging platforms, including strong growth in its SaaS-based sleep diagnostics business and expansion into global neuroimaging markets.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This content has been prepared as part of a partnership with Compumedics Limited and is intended for informational purposes only.
In its FY25 performance update, Compumedics announced record sales orders of $63.4 million, up 22% year-on-year. Revenue rose to $51 million, reflecting a +15% increase excluding the OrionMEG division. EBITDA came in at $2.9 million, a +9% increase from FY24. Gross margins were maintained at 55%.
The company’s Somfit SaaS platform delivered standout performance, with revenue increasing 49% year-on-year to $6.7 million, now accounting for 11% of total company revenue. The platform has surpassed 700,000 completed studies and holds over 75% share in the Australian HST pharmacy market.
Following FDA clearance, a $10M-plus U.S. sales pipeline has been established, supported by partnerships with Philips, ResMed, and pharmaceutical firms.
Initial U.S. sales include $2 million in orders from two global pharmaceutical companies, with additional trials anticipated through FY28. Compumedics highlighted a shift towards recurring SaaS revenues, noting over 800,000 studies completed across its Somfit and Nexus 360 platforms.
In neuroimaging, Compumedics is advancing its OrionMEG platform, securing orders for three systems in FY26, expected to generate around $15 million in revenue.
A broader $20 million sales pipeline is in development as well, particularly in China. Independent validation from the University of California, San Diego confirmed OrionMEG’s leadership in functional brain imaging. U.S. market entry is underway, with commercial launch expected in FY26.
Other lines also showed growth: Neuroscan and OKTI revenues doubled, CURRY sales rose 15%, and the DWL EZ-Dop received FDA and EU MDR approvals. Alpha Trace contributed €1M in sales through a new contract with Kepler Clinics.
For FY26, Compumedics is guiding for revenue above $70 million and EBITDA of approximately $9 million, driven by continued U.S. expansion of Somfit, OrionMEG system deliveries, and scaling SaaS operations.
Today, CMP shares are 31.5 cents each, heading into Friday’s trade.
Join the discussion. See what HotCopper users are saying about Compumedics Limited and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
